Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2011-04-26
2011-04-26
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C424S427000
Reexamination Certificate
active
07931909
ABSTRACT:
Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
REFERENCES:
patent: 4327725 (1982-05-01), Cortese et al.
patent: 4474451 (1984-10-01), Mizokami
patent: 4521210 (1985-06-01), Wong
patent: 4853224 (1989-08-01), Wong
patent: 4997652 (1991-03-01), Wong
patent: 5164188 (1992-11-01), Wong
patent: 5443505 (1995-08-01), Wong et al.
patent: 5501856 (1996-03-01), Ohtori et al.
patent: 5766242 (1998-06-01), Wong et al.
patent: 5824072 (1998-10-01), Wong
patent: 5869079 (1999-02-01), Wong et al.
patent: 6074661 (2000-06-01), Olejnik et al.
patent: 6242442 (2001-06-01), Dean et al.
patent: 6331313 (2001-12-01), Wong et al.
patent: 6369116 (2002-04-01), Wong et al.
patent: 6699493 (2004-03-01), Wong
patent: 2003/0060763 (2003-03-01), Penfold et al.
patent: WO 03/077952 (2003-09-01), None
patent: WO 2005/107705 (2005-11-01), None
patent: WO 2005/110362 (2005-11-01), None
patent: WO 2005/110367 (2005-11-01), None
patent: WO 2005/110368 (2005-11-01), None
Merkli, A., et al.,Use of Insoluble Biodegradable Polymers in Ophthalmic Systems for the Sustained Release of Drugs, European Journal of Pharmaceutics and Biopharmaceutics, Elsevier Science Publishers B.V., 1995, vol. 31, No. 5, pp. 271-283.
Barza et al., “The effects of infection and probenecid on the transport of carbenicillin from the rabbit vitreous humor”, Invest Ophthalmol Vis. Sci., 22:720-726 (1982).
Cheng et al., “Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-Hexadecylpropanediol-3-phospho-ganciclovir”, (2002) Investigative Ophthalmology & Visual Science, 43(2):515-521.
Cunha-Vaz et al., “The active transport of fluoroscein by the retinal vessels and the retina”, J. Physiol., 191:467-486 (1967).
Cunha-Vaz, “The blood-ocular barriers”, Surv. Ophthalmol., 5:279-296 (1979).
Han et al., “Characterization of a Novel Cationic Drug Transporter in Human Retinal Pigment Epithelial Cells”, Journal of Pharmacology and Experimental Therapeutics, 296(2): 450-457, 2001.
Heller, Biodegradable Polymers in Controlled Drug Delivery, In: CRC Critical Reviews in Therapeutic Drug Carrier Systems, vol. 1, CRC Press, Boca Raton, FL 1987, pp. 39-90.
Lesar et al., “Antimicrobial drug delivery to the eye”, Drug Intell Clin. Pharm., 19:642-654 (1985).
Maurice et al., “Handbook of Experimental Pharmacology: Pharmacology of the Eye”, Sears, Eds., vol. 69, (Springer-Verlag, Berlin-Heidelberg), 19-116 (1986).
Maurice, “Protein dynamics in the eye studied with labelled proteins”, Am J Ophthalmol, 49:361-367 (1959).
Maurice, “The exchange of sodium between the vitreous body and the blood and aqueous humor”, J. Physiol, 137:110-125 (1957).
Miller et al., “Fleroxacin pharmacokinetics in aqueous and vitreous humors determination by using complete concentration-time data from individual rabbits”, Antimicrob. Agents. Chemother., 36:32-38 (1992).
Sugiura et al., “Effects of intraocular pressure change on movement of FITC-dextran across vitreous-aqueous interface”, (1989), Jpn J. Ophthalmol, 33(4):441-450.
USP 23; NF 18 (1995) pp. 1790-1798.
Burke James A.
Chang-Lin Joan-En
Hughes Patrick M.
Allergan Inc.
Allergan, Inc.
Condino Debra D.
German Joel B.
Hartley Michael G
LandOfFree
Ocular therapy using alpha-2 adrenergic receptor compounds... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ocular therapy using alpha-2 adrenergic receptor compounds..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ocular therapy using alpha-2 adrenergic receptor compounds... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2626234